ST Renfu announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for HW252001 tablets approved and issued by the State Drug Administration. HW252001 tablets are intended for the treatment of idiopathic pulmonary fibrosis and are a new small-molecule drug taken orally. Up to now, the total R&D investment of the project is about RMB 20 million.

Zhitongcaijing · 2d ago
ST Renfu announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for HW252001 tablets approved and issued by the State Drug Administration. HW252001 tablets are intended for the treatment of idiopathic pulmonary fibrosis and are a new small-molecule drug taken orally. Up to now, the total R&D investment of the project is about RMB 20 million.